AstraZeneca’s CCP virus vaccine is producing an encouraging immune response among both older and younger adults, the drugmaker said on Oct. 26.
AstraZeneca, which is developing the possible vaccine along with the University of Oxford, said adverse responses to the vaccine among the elderly were found to be lower.